Abstract: All ten samples with the M184V mutation, three with the K65R, two with the G190A mutation, one with the K103N mutation, and one with the V75T mutation were detected similarly by all three assays.
Early virological failure in treatment-naive HIV-infected adults receiving didanosine and tenofovir plus efavirenz or nevirapine.
Abstract: At month 6, the mutations detected were K65R, L74V, L100I, K103N/R/T, Y181C and G190E/Q/S.
In vitro activity of structurally diverse nucleoside analogs against human immunodeficiency virus type 1 with the K65R mutation in reverse transcriptase.
PMID: 15728915
2005
Antimicrobial agents and chemotherapy
Abstract: Human immunodeficiency virus type 1 (HIV-1) with a lysine-to-arginine substitution at codon 65 (HIV-1(65R)) of reverse transcriptase (RT) can rapidly emerge in patients being treated with specific combinations of nucleoside analog RT inhibitors (NRTIs).
Diminished replicative fitness of primary human immunodeficiency virus type 1 isolates harboring the K65R mutation.
PMID: 15750116
2005
Journal of clinical microbiology
Abstract: A marked impairment in replicative fitness was observed in association with the selection of viruses carrying the K65R mutation in all patients.
Abstract: Here, we have used for the first time primary HIV-1 isolates from individuals who developed the K65R mutation while enrolled in a clinical trial of tenofovir to analyze the impact of this mutation on HIV-1 replicative fitness.
Abstract: The human immunodeficiency virus type 1 (HIV-1) reverse transcriptase (RT) resistance mutation K65R confers intermediate levels of resistance to several RT inhibitors, including a three- to fourfold reduction of tenofovir susceptibility.
Abstract: These results support a reduction in in vivo replication for K65R mutant viruses.
Early virological failure with a combination of tenofovir, didanosine and efavirenz.
Abstract: Additionally, L74V/I and K65R were detected in four and two patients, respectively.
Evaluation of an oligonucleotide ligation assay for detection of mutations in HIV-1 subtype C individuals who have high level resistance to nucleoside reverse transcriptase inhibitors and non-nucleoside reverse transcriptase inhibitors.
PMID: 15794978
2005
Journal of virological methods
Abstract: For codons, K103N, Y181C, K65R, Q151M, M184V and T215Y/F, four or more mismatches compared to the probe or mismatches less than four bases from the ligation site were not tolerated.
Abstract: The aim was to evaluate OLA for detecting mutations K103N, Y181C, K65R, Q151M, M184V and T215Y/F in subtype C.
Clonal analyses of HIV quasispecies in patients harbouring plasma genotype with K65R mutation associated with thymidine analogue mutations or L74V substitution.
Abstract: Moreover, the S68G and V75I mutations are not necessarily linked with K65R, and could thus have their own resistance effect.
Abstract: We analysed the quasispecies at a clonal level in patients whose plasma genotypic test harboured K65R with L74V or thymidine analogue mutations (TAM).
Abstract: We found no clone bearing both K65R and L74V substitutions.
Abstract: We showed that the K65R and TAM such as M41L, D67N, T215Y/D, L210W and K219E can be borne by the same virus.
High virological failure rate in HIV patients after switching to a regimen with two nucleoside reverse transcriptase inhibitors plus tenofovir.
Abstract: In addition, five genotypes harboring K65R with TAMs or L74V mutation were observed at failure.
Abstract: The K65R mutation can emerge even with TAMs or L74V.
Abstract: The K65R mutation, absent from all baseline genotypes, developed in 19 of the 96 patients, with an incidence significantly higher in group II than in group I.
Abstract: The selection of K65R was closely linked to the absence of TAMs at baseline and to the regimens sparing both protease inhibitors (PIs) and non-NRTIs.
HIV mutation literature information.
PMID: 
2005
Journal of clinical virology
Browser Board
Co-occurred Entities
Filtrator
ViMRT